Imatinib may be ABL to improve anti-angiogenic therapy.
We recently reported that neuropilin 1 (NRP1) drives angiogenesis by promoting extracellular matrix signaling in endothelial cells via ABL1 kinase. Imatinib targets this pathway in pathological angiogenesis and may provide a novel opportunity for anti-angiogenic therapy of age-related macular degeneration, proliferative diabetic retinopathy, or solid tumor growth.
UCL Institute of Ophthalmology; University College London ; London, UK.
Claudio
C
Raimondi
UCL Institute of Ophthalmology; University College London ; London, UK.
Alessandro
A
Fantin
UCL Institute of Ophthalmology; University College London ; London, UK.
Christiana
C
Ruhrberg